Prohost Biotech – Exclusive Biotech Research

Exclusive Market Insight

& Scientific analysis

  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Menu
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us

ARS Pharmaceuticals Announces FDA Approval of neffy® for Type I Allergic Reactions, Including Anaphylaxi in Pediatric Patients   

March 6, 2025 0
ARS Pharmaceuticals SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE), ARS Pharmaceuticals (SPRY) announced that the U.S. FDA has approved neffy® 1 mg (epinephrine nasal spray) for the treatment of Type I Allergy reactions, including anaphylaxis, in children who are aged 4 years and older and weigh 15 to < 30 kilograms (33 to < 66 lb.). This approval represents the first significant …

Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its...

Iterum Therapeutics Receives US FDA Approval of ORLYNVAH™ for the...

The United States FDA Approved Astellas’ product VYLOY in Combination...

U.S. FDA Approves AbbVie’s VYALEV™ for Adults Living with Advanced...

Novo Nordisk Launches New Initiative To Prevent Childhood Obesity In...

The FDA Approved IntraBio Product AQNEURSA As the only treatment...

Jeune Aesthetics: Reversing the Biology of Aging Skin to Meet...

Galderma Receives U.S. FDA Approval for Nemluvio® for Adult Patients...

SCG Cell Therapy: FDA Approved IND Application of Product SCG142...

Mitsubishi Tanabe Pharma America Announced the Presentations of its ND0612...

 AstraZeneca: The U.S. FDA Approved IMFINZI in Combination with Carboplatin...

Regeneron: Improved Hearing to Normal Levels in a Child with...

INmune Bio Inc. Update on Two Alzheimer Disease Patients Who...

Cerevel Therapeutics Announces Positive Results for Tavapadon in Phase 3...

Italfarmaco Received FDA Approval for Duvyzat™ for the Treatment of...

Abbott Laboratories Launches a New PROTALITY™ Brand to Maintain the...

Sanofi to Acquire Inhibrx, Inc.

Cognition Therapeutics CEO Issues Letter to Shareholders

For Migraine Patients and People Interested in New Migraine Results,...

Impacting News

Exelixis First Quarter 2025 Financial Results Plus Corporate Update

May 15, 2025 0
Exelixis in the NEWS   Two days ago, Exelixis (EXEL) reported financial results for the first quarter …

Will A Great Yesterday Erase The World’s Stress After U.S And China’s Agreement Over Tariffs? Also Read About The Resurrected CytomX Therapeutics 

May 13, 2025 0
Yesterday's Market and CytomX Therapeutics May 12, 2025 was an excellent day for many stressed countries. …

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 7, 2025 0
PTC Therapeutics On May 6, 2025, PTC Therapeutics (PTCT) announced a corporate update and financial results …

Important Biotechnology Companies’ News, Plus News from the American Association for Cancer Research and More 

April 29, 2025 0
Important News from AbbVie AbbVie (ABBV) submitted a biological license application (BLA) to the United States’ …

Vera Therapeutics ORIGIN Phase 3 Trial for Atacicept in IgAN

April 16, 2025 0
We still believe in many outperforming biotechnology firms whose stocks are underestimated on Wall Street. We …

Asking About the Most Recent Halozyme Therapeutics News

April 11, 2025 0
Halozyme Therapeutics Q & A Yesterday, Halozyme Therapeutics (HALO) announced that Argenx Company (ARGX) has received …

Trick or Trade

Answering Questions About Vera Therapeutics

May 19, 2025 0
Vera Therapeutics Q: What did Vera Therapeutics announce on May 6th that is more than what …

Altimmune, AstraZeneca and Alnylam Pharmaceuticals

March 17, 2025 0
Altimmune  Altimmune (ALT) stock soared last Friday after speculation of a takeover by three large companies. …

Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine

March 5, 2025 0
Moderna On February 28, 2025, Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency …

Can Cassava Sciences Resurrect When Simufilam is Used to Treat Seizures Related to Rare Neurodevelopmental Disorders Instead of Alzheimer’s Disease?

February 28, 2025 0
Cassava Sciences in the NEWS  Cassava Sciences, Inc. (SAVA) announced that it entered into an agreement …

Q & A About Alnylam Pharmaceuticals

February 19, 2025 0
Alnylam Pharmaceuticals Questions & Answers Q: Why has Alnylam Pharmaceuticals’ stock plummeted recently? A: We do …

Soon, Many Treatments for Life-Threatening Diseases Will Become History. Time to Select Biotech Companies With Novel Advanced Technologies and Products

February 18, 2025 0
 What About GRAIL Inc? GRAIL Inc (GRAL) is a healthcare company on a mission to detect …

Today’s Highlights

Alnylam Pharmaceuticals Reported Its Q1 2025 Financial Results and Highlights Recent Period Progress

May 1, 2025 0
Alnylam Pharmaceuticals Synopsis  Today, May 1, 2025 - Alnylam Pharmaceuticals (ALNY), the leading RNAi therapeutics company …

BridgeBio Pharma to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy at the ACC Annual Scientific Sessions

March 24, 2025 0
BridgeBio Pharma Today, March 24, 2025, BridgeBio Pharma, Inc. (BBIO) announced that cardiovascular outcomes data in patients …

FDA Approved Alnylam Pharmaceuticals sNDA for AMVUTTRA® – A Treatment for Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis in Adults to Reduce Cardiovascular Mortality, Cardiovascular Hospitalizations and Urgent Heart Failure Visits

March 21, 2025 0
Alnylam Pharmaceuticals in the NEWS March 20, 2025, Alnylam Pharmaceuticals (ALNY) - the leading RNAi therapeutics company, …

Two Companies: Pyxis Oncology Financial Results and Sarepta Therapeutics Unwarranted Selloff

March 18, 2025 0
Pyxis Oncology in the NEWS Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results …

A Little About the Stock Market and Some News from Johnson & Johnson

March 10, 2025 0
With a bad market and a lot of talk about recession and shutting down the Government, …

AstraZeneca: Imfinzi-based Regimen Demonstrated Statistically Significant and Clinically Meaningful Improvement in Event-free Survival in Resectable Early-Stage Gastric and Gastroesophageal Junction Cancers

March 7, 2025 0
AstraZeneca AstraZeneca (AZN) has positive high-level results from the MATTERHORN Phase III trial, which showed perioperative …

Latest Articlesddd

Answering Questions About Vera Therapeutics

May 19, 2025 0
Vera Therapeutics Q: What did Vera Therapeutics announce on May 6th that is more than what …

Exelixis First Quarter 2025 Financial Results Plus Corporate Update

May 15, 2025 0
Exelixis in the NEWS   Two days ago, Exelixis (EXEL) reported financial results for the first quarter …

Will A Great Yesterday Erase The World’s Stress After U.S And China’s Agreement Over Tariffs? Also Read About The Resurrected CytomX Therapeutics 

May 13, 2025 0
Yesterday's Market and CytomX Therapeutics May 12, 2025 was an excellent day for many stressed countries. …

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 7, 2025 0
PTC Therapeutics On May 6, 2025, PTC Therapeutics (PTCT) announced a corporate update and financial results …

Alnylam Pharmaceuticals Reported Its Q1 2025 Financial Results and Highlights Recent Period Progress

May 1, 2025 0
Alnylam Pharmaceuticals Synopsis  Today, May 1, 2025 - Alnylam Pharmaceuticals (ALNY), the leading RNAi therapeutics company …

Important Biotechnology Companies’ News, Plus News from the American Association for Cancer Research and More 

April 29, 2025 0
Important News from AbbVie AbbVie (ABBV) submitted a biological license application (BLA) to the United States’ …

Vera Therapeutics ORIGIN Phase 3 Trial for Atacicept in IgAN

April 16, 2025 0
We still believe in many outperforming biotechnology firms whose stocks are underestimated on Wall Street. We …

Asking About the Most Recent Halozyme Therapeutics News

April 11, 2025 0
Halozyme Therapeutics Q & A Yesterday, Halozyme Therapeutics (HALO) announced that Argenx Company (ARGX) has received …

Why and How the Stock Market Rallied Plus a Combination That Treated a Severe Colorectal Cancer

April 9, 2025 0
Today's Stock Market Rally Today, Wednesday, April 9, 2025 the news started with Trump announcing a …

Why Rhythm Pharmaceuticals Stock Rallied While The Market Was Tumbling

April 8, 2025 0
Rhythm Pharmaceuticals Rally Last week, almost all the stocks tumbled. On Monday, the first day of …

Novo Nordisk at ACC 2025: Ozempic® with Once Weekly Semaglutide 1mg Shown to Improve Walking Distance and Quality of Life in Adults with Type 2 Diabetes and Peripheral Artery Disease

April 3, 2025 0
Novo Nordisk in the NEWS Novo Nordisk (NVO) presented the full results from STRIDE, a phase …

The U.S. FDA Approved Alnylam Pharmaceuticals’ Product Qfitlia to Treat Hemophilia A or B With or Without Inhibitors

March 31, 2025 0
Stock Market Plummet and Alnylam Pharmaceuticals Good News Today, the stock market is plummeting. In fact, …

Wave Life Sciences Announced What Could be Excellent News in Treating Duchenne Muscular Dystrophy

March 28, 2025 0
Wave Life Sciences On March 26, 2025, Wave Life Sciences (WVE) announced positive data from the …

BridgeBio Pharma to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy at the ACC Annual Scientific Sessions

March 24, 2025 0
BridgeBio Pharma Today, March 24, 2025, BridgeBio Pharma, Inc. (BBIO) announced that cardiovascular outcomes data in patients …

Results from PTC Therapeutics’ Latest Presentation

March 24, 2025 0
PTC Therapeutics Inc On March 20, 2025, PTC Therapeutics, Inc. (PTCT) shared new data from the Phase 3 APHENITY …

FDA Approved Alnylam Pharmaceuticals sNDA for AMVUTTRA® – A Treatment for Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis in Adults to Reduce Cardiovascular Mortality, Cardiovascular Hospitalizations and Urgent Heart Failure Visits

March 21, 2025 0
Alnylam Pharmaceuticals in the NEWS March 20, 2025, Alnylam Pharmaceuticals (ALNY) - the leading RNAi therapeutics company, …

Two Companies: Pyxis Oncology Financial Results and Sarepta Therapeutics Unwarranted Selloff

March 18, 2025 0
Pyxis Oncology in the NEWS Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results …

Altimmune, AstraZeneca and Alnylam Pharmaceuticals

March 17, 2025 0
Altimmune  Altimmune (ALT) stock soared last Friday after speculation of a takeover by three large companies. …

A Little About the Stock Market and Some News from Johnson & Johnson

March 10, 2025 0
With a bad market and a lot of talk about recession and shutting down the Government, …

AstraZeneca: Imfinzi-based Regimen Demonstrated Statistically Significant and Clinically Meaningful Improvement in Event-free Survival in Resectable Early-Stage Gastric and Gastroesophageal Junction Cancers

March 7, 2025 0
AstraZeneca AstraZeneca (AZN) has positive high-level results from the MATTERHORN Phase III trial, which showed perioperative …

Posts pagination

1 2 3 4 … 76 Next

Prohost Letters

Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis

August 21, 2024 0
Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ (GILD) …

Prohost Letter #460 ~ Treating IgA Nephropathy

June 1, 2024 0
Prohost Letter #460 Treating IgA Nephropathy Immunoglobulin A (IgA), the antibody of the immune system known …

Prohost Letter #459 ~ NAFLD & NASH

March 3, 2024 0
Prohost Letter #459 ~ NAFLD & NASH NAFLD is Non-Alcoholic Fatty Liver Disease, and NASH is …

Prohost Letter #458 ~ Obesity

December 18, 2023 0
Prohost Letter #458 ~ Obesity Finally, obesity is being recognized as a severe sickness. Indeed, obesity …

Discovering The Root Causes of Diseases

September 15, 2023 0
Prohost Letter #457 Discovering The Root Causes of Diseases   Biotech firms with solid scientific fundamentals …

Treatments for Untreatable Diseases

July 16, 2023 0
Prohost Letter #456 Treatments for Untreatable Diseases The revolution in biotechnology is not meant to offer …

Search ProhostBiotech

Popular Links

Aerie Pharmaceuticals (AERI) Agenus (AGEN) Alnylam Pharmaceuticals (ALNY) Amgen (AMGN) Array BioPharma (ARRY) AstraZeneca Plc (AZN) Bellicum Pharmaceuticals Inc (BLCM) Bristol-Myers Squibb (BMY) Celgene (CELG) Celldex Therapeutics (CLDX) Cellectis (CLLS) Celyad (CYAD) Compugen (CGEN) CRISPR Therapeutics (CRSP) CytomX Therapeutics Inc (CTMX) Editas Medicine Inc (EDIT) Enanta Pharmaceuticals (ENTA) Exelixis (EXEL) Gilead Sciences (GILD) Halozyme Therapeutics (HALO) Illumina (ILMN) ImmunoGen (IMGN) Incyte (INCY) Innoviva (INVA) Intellia Therapeutics (NTLA) Ionis Pharmaceuticals Inc (IONS) Karyopharm Therapeutics Inc (KPTI) Merck (MRK) Moderna Inc (MRNA) Nektar Therapeutics (NKTR) Neurocrine Biosciences (NBIX) Novartis (NVS) Portola Pharmaceuticals Inc (PTLA) PTC Therapeutics (PTCT) Regeneron Pharmaceuticals (REGN) Regenxbio (RGNX) Rhythm Pharmaceuticals Inc (RYTM) Sangamo Therapeutics Inc (SGMO) Sarepta Therapeutics (SRPT) Seagen Inc (SGEN) Spark Therapeutics Theravance Biopharma (TBPH) Vertex Pharmaceuticals (VRTX) Xoma (XOMA)
  • Recent

ProhostBiotech Archive

Sign Up for Weekly Emails

Prohost Biotech – Exclusive Biotech Research Copyright © 2025.
© 2014 Prohost Biotech. All rights reserved.

Privacy Policy | Cancellation Policy | Forward Looking Statement

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptPrivacy policy